Fig. 4.

Management of cardiotoxicity based on the clinical manifestations and the severity of the cardiotoxicity. It is recommended to utilize identical imaging modalities, biomarkers, and other laboratory parameters during different follow-up stages for comparability. Reduction in GLS is considered significant when there is a ≥ 12% relative decrease or ≥ 5% absolute decrease. 2D- 2-dimensional; 3D, 3-dimensional; ACEI, Angiotensin Converting Enzyme Inhibitor; ARB, Angiotensin Receptor Blockers; BB, Beta Blockers; CMR, Cardiac Magnetic Resonance imaging; GLS, Global Longitudinal Strain; HER, human epidermal growth factor receptor; IHD, Ischemic Heart Disease; PAD, Peripheral Artery Disease; and VEGF, Vascular Endothelial Growth Factor